Vectors Research Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Vectors Research Management’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-500	Closed	-$1K	–	573
2019 Q4	$1K	Hold	500	–	–	﹤0.01%	532
2019 Q3	$1K	Hold	500	–	–	﹤0.01%	467
2019 Q2	$1K	Hold	500	–	–	﹤0.01%	418
2019 Q1	$1K	Buy	+500	New	+$1.06K	﹤0.01%	416

Other funds holding NYMX

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Vectors Research Management's NYMX Position: Q1 2020 in Review

Vectors Research Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2020, closing a stake of 500 shares — an estimated $1K sold.

Vectors Research Management first reported a position in NYMX in Q1 2019 and held it in 4 quarters. The position peaked at $1K in Q4 2019. 47 funds tracked by Wall St. Rank hold NYMX as of Q1 2020.

Vectors Research Management reported no remaining Nymox Pharmaceutical Corp position as of Q1 2020 after selling out during the quarter.
Vectors Research Management sold 500 Nymox Pharmaceutical Corp shares in Q1 2020, an estimated $1K.
Vectors Research Management first reported a position in Nymox Pharmaceutical Corp in Q1 2019 and held it in 4 quarters.
Vectors Research Management's Nymox Pharmaceutical Corp position peaked at $1K in Q4 2019.
47 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2020.

Based on Vectors Research Management's 13F filing for Q1 2020, filed 14 May 2020.